AstraZeneca CEO hopes U.S. will represent half of company’s global revenue by 2030—vows to invest and expand in nation despite tariff threat

British pharmaceutical giant AstraZeneca on Tuesday vowed to keep investing and growing its business in the United States, ahead of President Donald Trump's possible tariffs on the sector.

"Our company is firmly committed to investing and growing in the US," chief executive Pascal Soriot said in an earnings statement, which also announced that first quarter profit had risen by over 30 percent to $2.92 billion.

The United States earlier in April opened the door to potential tariffs targeting pharmaceuticals...